Selective improvement of thymus and some T cell dysfunctions in NZB mice by in utero thymulin treatment.
NZB mice were treated during gestation with thymulin, a thymus-secreted, zinc-associated nonapeptide. Control pregnant NZB mice received either zinc alone or saline alone. Offspring from all three groups of NZB mothers, and age-matched DBA/2 mice, were tested for the following immunologic parameters: thymulin serum levels at 2 and 5 wk of age; splenic anti-sheep red blood cell (anti-SRBC) plaque-forming cell (PFC) numbers after immunization at birth or at 2 wk of age; anti-human gamma-globulin (anti-HGG) antibody titers after immunization at 2 wk of age, with or without prior tolerance induction at birth with deaggregated HGG; spontaneous IgM serum levels at 2 and 5 wk of age; spontaneous splenic anti-trinitrophenyl (anti-TNP) PFC numbers at 2 wk of age. As compared with DBA/2 mice, young NZB mice exhibited low circulating thymulin titers, high antibody responses to SRBC and to HGG, resistance to tolerance induction by deaggregated HGG, increased spontaneous IgM serum levels, and increased spontaneous anti-TNP PFC numbers. However, marked reductions in anti-SRBC and anti-HGG antibody production, both thymus-dependent responses, were observed in the young NZB offspring of thymulin-treated mothers as compared with NZB controls born from zinc- or saline-treated mothers. A delay in the postnatal decrease of serum thymulin levels was also noted in the offspring of thymulin-treated mothers. Interestingly, these effects of in utero thymulin treatment tended to become more pronounced with advancing age during the postnatal period. Conversely, IgM serum levels, spontaneous anti-TNP PFC and sensitivity to tolerance induction were not affected by thymulin treatment during fetal life. Taken together, the data suggest that in utero exposure to pharmacologic concentrations of thymulin induces a persistent and selective improvement of some thymus and T cell dysfunctions but has no effect on intrinsic B cell abnormalities of NZB mice.
Quéré
P
P
Dardenne
M
M
Bach
M A
MA
D000818:Animals; D000831:Animals, Newborn / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D005260:Female; D006462:Hemolytic Plaque Technique; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007112:Immunity, Maternally-Acquired / Q000187:drug effects*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D008814:Mice, Inbred NZB / Q000276:immunology*; D011247:Pregnancy; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D013935:Thymic Factor, Circulating / Q000097:blood / Q000627:therapeutic use*; D013950:Thymus Gland / Q000166:cytology / Q000276:immunology* / Q000503:physiopathology; D013951:Thymus Hormones / Q000627:therapeutic use*; D005719:gamma-Globulins / Q000276:immunology
D013951:Thymus Hormones; D005719:gamma-Globulins; D013935:Thymic Factor, Circulating